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Development and psychometric evaluation of the
Transdiagnostic Decision Tool: matched care for
patients with a mental disorder in need of highly
specialised care
Frédérique C. W. van Krugten, Christina M. van der Feltz-Cornelis, Manon A. Boeschoten,
Saskia A. M. van Broeckhuysen-Kloth, Jonna F. van Eck van der Sluijs, Elisa van Ee,
Saskia M. van Es, Maartje Schoorl, Lineke M. Tak, Werner B. F. Brouwer and
Leona Hakkaart-van Roijen, on behalf of the Transdiagnostic Decision Tool Consortium*
Background
Early identification of patients with mental health problems in
need of highly specialised care could enhance the timely provi-
sion of appropriate care and improve the clinical and cost-
effectiveness of treatment strategies. Recent research on the
development and psychometric evaluation of diagnosis-specific
decision-support algorithms suggested that the treatment allo-
cation of patients to highly specialised mental healthcare set-
tings may be guided by a core set of transdiagnostic patient
factors.
Aims
To develop and psychometrically evaluate a transdiagnostic
decision tool to facilitate the uniform assessment of highly spe-
cialised mental healthcare need in heterogeneous patient
groups.
Method
The Transdiagnostic Decision Tool was developed based on an
analysis of transdiagnostic items of earlier developed diagnosis-
specific decision tools. The Transdiagnostic Decision Tool was
psychometrically evaluated in 505 patients with a somatic
symptom disorder or post-traumatic stress disorder. Feasibility,
interrater reliability, convergent validity and criterion validity
were assessed. In order to evaluate convergent validity, the five-
level EuroQol five-dimensional questionnaire (EQ-5D-5L) and the
ICEpop CAPability measure for Adults (ICECAP-A) were
administered.
Results
The six-item clinician-administered Transdiagnostic Decision
Tool demonstrated excellent feasibility and acceptable interrater
reliability. Spearman’s rank correlations between the
Transdiagnostic Decision Tool and ICECAP-A (−0.335), EQ-5D-5L
index (−0.386) and EQ-5D-visual analogue scale (−0.348)
supported convergent validity. The area under the curve was
0.81 and a cut-off value of≥3 was found to represent the optimal
cut-off value.
Conclusions
The Transdiagnostic Decision Tool demonstrated solid psycho-
metric properties and showed promise as a measure for the
early detection of patients in need of highly specialised mental
healthcare.
Keywords
Screening; academic psychiatry; highly specialized care; early
identification; assessment.
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Background
Although the efficacy of psychological interventions for the treat-
ment of a wide range of mental health problems is well estab-
lished,1,2 a significant number of patients require multiple
treatment steps to achieve an adequate treatment response.3 An
inadequate response to initial treatment, in turn, is associated
with higher relapse rates, chronicity3 and substantial societal
costs.4 Against this background, and given the increasing preva-
lence5 and high associated costs6 of mental health problems, the
importance of matching patients to the most appropriate level
and type of initial care is increasingly recognised.
The matched-care approach, in which pre-treatment patient
characteristics are used to match patients to the level of care that
is likely to be most beneficial to them,8 has the potential to
improve the clinical effectiveness and cost-effectiveness of treat-
ment strategies.9 Matched care has been demonstrated to be an
appropriate and effective approach in patients with mental health
problems attending the primary care setting,10,11 the occupational
healthcare setting12 and the out-patient general hospital setting,13
but is likely to be most beneficial for the subgroup of patients in
need of highly specialised mental healthcare. Often, these patients
demonstrate low response and high relapse rates after initial treat-
ment,14,15 and require additional treatment steps as the result.
The provision of matched care in this subgroup is therefore war-
ranted, but strongly relies on the ability to identify these patients
and therefore the availability of pre-treatment assessment tools
and decision guidelines to accurately match the initial treatment
to the individual patient needs.16,17
Recent initiatives to inform treatment decisions by pre-treat-
ment patient characteristics include the development of diagnosis-
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specific decision tools for the following diagnostic groups: personal-
ity disorders, eating disorders, unipolar depression and anxiety
disorders.18–21 Decision tools are brief, clinician-administered
instruments, especially designed to identify patients in need of
highly specialised care during the diagnostic phase. Decision tools
items include pre-treatment patient characteristics such as the
absence or presence of psychiatric or somatic comorbidity, and
the total score is an indicator of the need for highly specialised
care. These diagnosis-specific decision tools have demonstrated
solid psychometric properties,18–21 and are used in psychiatric
specialised centres to enhance the early identification of patients
with a highly specialised mental healthcare need.
Aims
The development and psychometric evaluation of these diagnosis-
specific decision tools suggested that the allocation of patients to
highly specialised mental healthcare settings may be guided by a
core set of transdiagnostic patient factors. Building on the theoret-
ical foundations of, and insights from, the development of these
diagnosis-specific decision tools, the aim of this study was to
explore the possibility of developing a transdiagnostic decision
tool for use in heterogeneous patient groups, in patients with a diag-
nosis for which no diagnosis-specific decision tool is available and in
patients without a clear primary diagnosis. Such a tool could
enhance the systematic and standardised early identification of
patients with a highly specialised mental healthcare need, which,
in turn may enhance treatment outcomes in patients with severe
and complex mental health problems.
Method
Definition of terms and Transdiagnostic Decision Tool
development
Highly specialisedmental healthcare (i.e. tertiary mental healthcare)
is the care provided by highly trained professionals to individuals
with mental health problems that are complex and refractory to
interventions provided in specialised (for example secondary)
mental healthcare settings such as community mental health
centres and general hospitals.22,23 Given the level of necessary
staff expertise, assessment and resources, highly specialised
mental healthcare is often, but not per definition, provided in
mental healthcare centres affiliated with academic medical
settings.22
In order to enhance the early identification and adequate man-
agement of patients with mental health problems in need of highly
specialised care, the following four diagnosis-specific decision
support algorithms were developed: the Decision Tool Personality
Disorders,19 the Decision Tool Eating Disorders,18 the Decision
Tool Unipolar Depression20 and the Decision Tool Anxiety
Disorders.21 Building on the theoretical foundations of, and insights
from, the development and psychometric evaluation of these diag-
nosis-specific decision tools, the Transdiagnostic Decision Tool
was developed for use in heterogeneous patient groups, in patients
with a diagnosis for which no diagnosis-specific decision tool is
available and in patients without a clear primary diagnosis.
The tool was initially intended for use in the diagnostic phase in
specialised mental healthcare centres in order to optimise the clin-
ical decision-making process in the referral of patients with mental
health problems to highly specialised care. Its use does not have to
be restricted to this setting, however. The Transdiagnostic Decision
Tool was developed by the Transdiagnostic Decision Tool
Consortium, comprising 16 leading mental health experts
(psychiatrists and psychologists), two academics and two patient
representatives (see Acknowledgements).
The development process of the Transdiagnostic Decision Tool
consisted of three consecutive phases.
(a) In the first phase, the overlapping patient criteria in the diagno-
sis-specific decision tools were established.
(b) In the second phase, consortium members generated the draft
Transdiagnostic Decision Tool through operationalisation of
each of the criteria identified in the first phase.
(c) In the third phase, a pilot study was carried out in 34 patients
with a DSM-524 diagnosis of post-traumatic stress disorder
(PTSD) (n = 10), somatic symptom disorder (SSD) (n = 10),
unipolar depression (n = 5), anxiety disorder (n = 2), eating
disorder (n = 3), personality disorder (n = 3) or psychotic
disorder (n = 1) who were referred for treatment to either a
specialised or highly specialised treatment centre in the
Netherlands. Clinicians were asked to complete the draft
version of the Transdiagnostic Decision Tool and answer ques-
tions regarding its feasibility. Feasibility questions included the
total time required to complete the tool and the clarity of the
item wording and the tool in total.
Evaluation of psychometric properties
Study design and population
In order to evaluate the psychometric properties of the
Transdiagnostic Decision tool, a cross-sectional, observational mul-
ticentre study was carried out in eight specialised (general psychi-
atric) and highly specialised (i.e. tertiary) mental healthcare clinics
in the Netherlands under routine care conditions. To facilitate the
comparison of psychometric properties between diagnoses groups
and evaluate the transdiagnostic robustness of the Transdiagnostic
Decision tool, the study was carried out in two distinct diagnostic
groups. The study population consisted of 505 adult (18 years and
older) psychiatric out-patients with either a primary diagnosis of
SSD or a primary diagnosis of PTSD according to DSM-5 criteria.
Written informed consent was obtained from all patients. The
authors assert that all procedures contributing to this work comply
with the ethical standards of the relevant national and institutional
committees on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2008. All procedures involving
human patients were approved by the Medical Ethical Committee
of the Erasmus University Medical Centre Rotterdam, the
Netherlands (MEC-2017-051).
Measures
In addition to the Transdiagnostic Decision Tool that was com-
pleted by the clinician, participants also completed a number of
self-report instruments.
(a) The five-level EuroQol five-dimensional questionnaire (EQ-
5D-5L)25 is a generic, standardised, self-administered
measure of health-related quality of life (HRQoL). The EQ-
5D-5L comprises two parts: a descriptive system and a visual
analogue scale (EQ-5D-VAS). The descriptive system consists
of five items, covering five dimensions (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression),
each with five response levels (no problems, some problems,
moderate problems, severe problems and extreme problems/
unable to). The answers on the descriptive system can be con-
verted into a single preference-based summary index score (the
EQ-5D-5L index) by applying societal preference weights to
the self-classified health states. Based on the Dutch national
value set, EQ-5D-5L index scores can range from −0.446
(representing the worst health state) to 1 (representing the
van Krugten et al
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best health state).26 The second part of the EQ-5D-5L, the EQ-
5D-VAS, records the respondent’s current self-rated health on
a 20 cm vertical scale ranging from zero (‘the worst health you
can imagine’) to 100 (‘the best health you can imagine’).
(b) The ICEpop CAPability measure for Adults (ICECAP-A)27 is a
generic, standardised, self-administered measure of capability
well-being for use in the adult population. The descriptive
system consists of five items, covering five dimensions (stabil-
ity, attachment, autonomy, achievement and enjoyment), each
with four response levels. Responses to the descriptive system
can be converted into a single summary index by applying soci-
etal preference weights to the self-classified capability states.
The ICECAP-A index can range from 0 (representing the
absence of capability) to 1 (representing full capability).28
Procedures
FromMarch 2017 throughMarch 2018, patients were enrolled in the
study at eight specialised (general psychiatric) and highly specialised
(i.e. tertiary) mental healthcare clinics in the Netherlands. During
the intake interview, clinicians rated each participating patient
on the Transdiagnostic Decision Tool and entered the scoring
on the Transdiagnostic Decision Tool, as well as demographic and
clinical characteristics (gender, age, country of origin, primary diag-
nosis) and two questions regarding the feasibility of using the
Transdiagnostic Decision Tool into web-based case report forms.
Feasibility was operationalised as the total administration time of
the Transdiagnostic Decision Tool, the clarity of the total set of
items (scored as ‘Yes’ or ‘No’) and the percentage of missing values.
In order to evaluate the interrater reliability, a random sub-
sample of 28% of patients was rated on the Transdiagnostic
Decision Tool by a second clinician present at the intake interview.
During the intake interview, patients completed a three-page ques-
tionnaire, including the EQ-5D-5L and the ICECAP-A to assess the
convergent validity. Based on the patients’ preference, the EQ-5D-
5L was provided in Dutch, English, French or Arabic and the
ICECAP-A in Dutch or English.
Criterion validity was evaluated in a random subsample of 59%
of patients by comparing the total Transdiagnostic Decision Tool
score with the clinical judgement of senior clinicians. Two clinicians
independently and masked to the individual scores on the
Transdiagnostic Decision Tool rated whether the patient was in
need of highly specialised care (scored with ‘Yes’ or ‘No’). An inde-
pendent researcher verified the consistency between the judge-
ments, and disagreements were resolved by discussion or through
third-party consultation.
Statistical analysis
Demographic and clinical characteristics of the study sample and
feasibility data were analysed using descriptive statistics. In line
with previous Decision Tool research,20,21 criteria for feasibility
success were set at a mean administration time of ≤10 minutes,
content clarity judged as ‘clear’ in ≥90% of all evaluations, and
≤5% of missing item responses.
To assess the interrater reliability, Krippendorff’s alpha reliabil-
ity coefficients29,30 were calculated for each of the individual items,
and the total Transdiagnostic Decision Tool score. The minimum
acceptable reliability level was set at 0.667.30 Following Shapiro–
Wilk tests of normality, non-parametric Spearman’s rank correla-
tions between the total Transdiagnostic Decision Tool scores and
EQ-5D-5L index, EQ-5D-VAS and ICECAP-A scores were computed
to assess convergent validity. Correlations of 0.10–0.29, 0.30–0.49 and
≥0.50 were considered weak, moderate and strong, respectively.31
TransdiagnosticDecisionTool scoreswere expected tohave amoderate
negative correlation with HRQoL (EQ-5D-5L) and well-being
(ICECAP-A) scores. Receiver-operating characteristic (ROC) curves
were generated to assess the criterion validity and to determine the
optimal cut-off score. Areas under the ROC curves (AUCs) were gen-
erated to summarise the discriminative accuracy of theTransdiagnostic
Decision Tool. In order to determine the optimal cut-off score, a
Youden index (J = (sensitivityc + specificityc)−1)
32 was calculated for
each possible cut-off score. The cut-off score that corresponded to
the highest Youden index was selected as the optimal cut-off score.
All statistical analyses were carried out both for the total sample
and for each diagnostic group and conducted using IBM SPSS
(Statistical Package for the Social Sciences) version 24.0 (SPSS
Inc., IBM Corporation, Armonk, New York, USA). Significance
levels were set at P < 0.05 (two-tailed).
Results
Scale development and preliminary evaluation of the
criterion validity
Analysis of the overlapping criteria in the diagnosis-specific deci-
sion tools revealed the following five transdiagnostic criteria to
detect patients with a highly specialised care need: high severity
level of the primary diagnosis; treatment-interfering psychiatric
comorbidity; treatment-interfering somatic comorbidity; treat-
ment-interfering psychosocial dysfunctioning; and previous unsuc-
cessful treatment of the current primary diagnosis in specialised
mental healthcare (see Supplementary file A available at https://
doi.org/10.1192/bjo.2020.74 for the primary items of the diagno-
sis-specific decision tools).
In a consensus meeting, consortium members added the criter-
ion ‘Severe or longstanding childhood trauma’ to the initial list of
five criteria given the prognostic importance of this criterion in
patients with mental health problems.33 In line with the diagno-
sis-specific decision tools, each of the transdiagnostic criteria was
operationalised into a dichotomous (item present or not) scale
item, resulting in a six-item draft version of the Transdiagnostic
Decision Tool. Based on the data of the pilot study, no adjustments
to the wording of items were needed. The items, response options,
and scoring system of the Transdiagnostic Decision tool are pre-
sented in Table 1. An English translation of the complete
Transdiagnostic Decision Tool is presented in Supplementary file B.
Table 1 Items, response options and scoring system of the
Transdiagnostic Decision Tool
Item,a response options Score
1. Severe primary diagnosis
Yes 1
No 0
2. Treatment-interfering psychiatric comorbidity
Yes 1
No 0
3. Treatment-interfering somatic comorbidity
Yes 1
No 0
4. Treatment-interfering psychosocial dysfunctioning
Yes 1
No 0
5. Severe or longstanding childhood trauma
Yes 1
No 0
6. Previous unsuccessful treatment of the current primary
diagnosis in specialised care
Yes 1
No 0
a. Item text is abbreviated. An English translation of the complete Transdiagnostic
Decision Tool is presented in Supplementary file B.
Development and psychometric evaluation of the Transdiagnostic Decision Tool
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Psychometric evaluation
In total, 505 patients were enrolled in the study. The demographic
and clinical characteristics of the study population are presented in
Table 2. The mean age of the patients was 41.2 years (s.d. = 12.4;
range 18–79), 281 patients (55.6%) were women, and the majority
of patients (71.1%) were of Dutch origin. At presentation, 234
(46.3%) patients had a primary diagnosis of SSD, and 271 (53.7%)
had a primary diagnosis of PTSD. The mean total Transdiagnostic
Decision Tool score was 2.5 (s.d. = 1.8; range 0–6). Mean
self-reported HRQoL and well-being scores as measured by the
EQ-5D-5L, EQ-5D-VAS and ICECAP-A were 0.40 (s.d. = 0.30;
range−0.35 to –1.00), 49.7 (s.d. = 19.7, range 0.0–100.0) and 0.58
(s.d. = 0.20; range 0.00–0.97), respectively.
Feasibility
Mean administration time of the Transdiagnostic Decision Tool was
6.9 min (s.d. = 4.2; range = 1–30), and the total set items was evalu-
ated as ‘clear’ in a vast majority of the evaluations (96.6%). The
mean administration time was significantly lower (P < 0.001) in
patients with SSD (5.6 min; s.d. = 3.1) than in patients with PTSD
(8.0 min; s.d. = 4.6). The percentage of missing item responses
ranged from 0.0% (item 6) to 1.5% (item 5) (mean 0.8%).
Interrater reliability
As shown in Table 3, Krippendorff’s alpha values ranged from 0.724
(95% CI 0.581–0.841) for item 4 (‘psychosocial dysfunctioning’) to
0.848 (95% CI 0.731–0.938) for item 5 (‘childhood trauma’) in the
total interrater reliability sample. In the SSD subsample, the
Krippendorff’s alpha values of item 3 (‘somatic comorbidity’) and
item 4 (‘psychosocial dysfunctioning’) fell short of the recom-
mended reliability level of 0.667. All other Krippendorff’s alpha
values of the individual items and the total Transdiagnostic
Decision Tool score exceeded the recommended reliability level.
Validity
As hypothesised, Transdiagnostic Decision Tool sum scores negatively
correlated with HRQoL and well-being scores as measured by the EQ-
5D-5L (rs(485) =−0.386; P < 0.001), EQ-5D-VAS (rs(485) =−0.348;
P < 0.001), and ICECAP-A (rs(485) =−0.335; P < 0.001). As shown
in Fig. 1, the AUC in the total criterion validity sample (n = 298) was
0.81 (95% CI 0.76–0.86; P < 0.001). The AUC in the SSD and PTSD
subsamples were 0.84 (95% CI = 0.77–0.90; P < 0.001) and 0.78 (95%
CI = 0.71–0.86; P < 0.001), respectively. The accuracy indices for
various cut-off values of the Transdiagnostic Decision Tool are pre-
sented in Table 4. Based on the highest Youden index (Jmax) of 0.474
(sensitivity 72.4%; specificity 75.0%), the optimal cut-off value for the
Transdiagnostic Decision Tool was ≥3 in the total criterion validity
sample (n = 298). The optimal cut-off value of ≥3 was also found in
the SSD (Jmax = 0.536) and PTSD (Jmax = 0.436) subsample.
Discussion
Main findings
This paper reports on the development and psychometric evalu-
ation of a measure aimed at aiding clinicians in the early
Table 2 Demographic and clinical characteristics of the study sample
Total sample IRR samplea Criterion validity samplea
N 505 140 298
Age, years
Mean (s.d.) 41.2 (12.4) 41.9 (13.2) 41.4 (12.5)
Range 18–79 18–79 18–79
Gender (n, %)
Men 224 (44.4) 60 (42.9) 116 (38.9)
Women 281 (55.6) 80 (57.1) 182 (61.1)
Country of origin, n (%)
The Netherlands 359 (71.1) 109 (77.9) 201 (67.4)
Surinam 19 (3.8) 3 (2.1) 10 (3.4)
Turkey 16 (3.2) 2 (1.4) 13 (4.4)
Morocco 14 (2.8) 4 (2.9) 11 (3.7)
Iraq 12 (2.4) 3 (2.1) 10 (3.4)
Syria 11 (2.2) 2 (1.4) 7 (2.3)
Afghanistan 8 (1.6) 2 (1.4) 2 (0.7)
Other 65 (12.9) 15 (10.7) 43 (14.4)
Missing 1 (0.2) 0 (0.0) 1 (0.3)
Diagnosis, n (%)
Somatic symptom disorder 234 (46.3) 87 (62.1) 155 (52.0)
Post-traumatic stress disorder 271 (53.7) 53 (37.9) 143 (48.0)
Total Decision Tool score
Mean (s.d.) 2.52 (1.76) 2.66 (1.83) 2.62 (1.70)
Range 0–6 0–6 0–6
EQ-5D-5L index
Mean (s.d.) 0.40 (0.30) 0.40 (0.31) 0.37 (0.31)
Range −0.35 to 1.00 −0.35 to 1.00 −0.35 to 1.00
Missing, n (%) 20 (4.0) 3 (2.1) 10 (3.4)
EQ-5D-VAS
Mean (s.d.) 49.7 (19.7) 48.45 (19.07) 47.11 (19.11)
Range 0.0–100.0 0.00–100.00 0.00–90.00
Missing, n (%) 20 (4.0) 3 (2.1) 10 (3.4)
ICECAP-A index
Mean (s.d.) 0.58 (0.20) 0.61 (0.20) 0.58 (0.21)
Range 0.00–0.97 0.08–0.97 0.00–0.97
Missing, n (%) 23 (4.6) 3 (2.1) 12 (4.0)
EQ-5D-5L, Five-level EuroQol five-dimensional questionnaire; ICECAP-A, ICEpop CAPability measure for Adults; IRR, interrater reliability; VAS, visual analogue scale.
a. Part of total sample.
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identification of patients with mental health problems in need of
highly specialised care, the Transdiagnostic Decision Tool. Items
of the Transdiagnostic Decision Tool were established through
identification of overlapping criteria in previously developed diag-
nosis-specific decision tools. Overall, the results of the present
study suggest that the Transdiagnostic Decision Tool is a psycho-
metrically sound, and with the establishment of a cut-off score,
promising tool for the early identification of patients with mental
health problems in need of highly specialised care.
Interpretation of the findings
The short mean administration time (6.9 min) and low rate of
missing values (mean 0.8%) supported the use of the
Transdiagnostic Decision Tool in busy clinical settings. In the
total sample, all Krippendorff’s alpha values exceeded the recom-
mended reliability level of 0.667,33 demonstrating acceptable inter-
rater reliability. However, the Krippendorff’s alpha values of item 3
(‘somatic comorbidity’) and item 4 (‘psychosocial dysfunctioning’)
fell short of the recommended reliability level in the SSD subsample.
Analyses of the qualitative feedback regarding item 3 suggested that
the lower Krippendorff’s alpha might be because of the differential
classification of medically unexplained physical symptoms across
items. In other words, in some instances, clinicians may have clas-
sified medically unexplained physical symptoms under item 3
(‘somatic comorbidity’) instead of under items concerning the
primary diagnosis, such as item 1 (‘severity’). The provided qualita-
tive feedback provided no explanation for the lower Krippendorff’s
alpha of item 4. Future studies should evaluate whether further spe-
cification and clarification of scoring instructions for items 3 and 4
could improve the interrater reliability of these items in patients
with SSD.
The Transdiagnostic Decision Tool demonstrated excellent val-
idity, both in the total sample and within each diagnostic group.
Specifically, the total Transdiagnostic Decision Tool score demon-
strated meaningful patterns of correlations with total HRQoL and
well-being scores, supporting convergent validity. In addition, the
AUC in the total criterion validity sample was 0.81, and a cut-off
value of 3 or greater on the Transdiagnostic Decision Tool was
found to be the optimal cut-off value both in the total sample and
within each diagnostic group, indicating that the optimal cut-off
value is uniform across these diagnostic groups. Hence, the findings
of the present study suggest that although disorder-specific symp-
toms are the predominant factors defining differential diagnoses,
the allocation of patients to highly specialised healthcare may be
meaningfully guided by a core set of transdiagnostic patient factors.
Strengths and limitations
This study has a number of strengths, including the large sample
size, the population-based design and the examination of important
psychometric properties related to the use of the Transdiagnostic
Decision Tool in daily clinical practice. However, several limitations
should also be noted.
First, in the absence of a reference test for the systematic and
standardised early identification of patients with a highly specialised
mental healthcare need, the clinical judgement of clinicians was the
reference standard for the evaluation of the criterion validity.
Although the use of the clinical judgement as the reference standard
may have introduced subjective error, effort was made to reduce
error by basing the final clinical judgement on dual, independently
Table 3 Krippendorff’s alpha values of the Transdiagnostic Decision Tool
Item
Total interrater reliability sample
(n = 140)
Somatic symptom disorder
(n = 87)
Post-traumatic stress disorder
(n = 53)
1. Severity 0.733 (0.582–0.868) 0.748 (0.614–0.871) 0.704 (0.552–0.843)
2. Psychiatric comorbidity 0.754 (0.618–0.879) 0.720 (0.568–0.849) 0.763 (0.630–0.877)
3. Somatic comorbidity 0.753 (0.611–0.886) 0.655 (0.498–0.791)a 0.941 (0.846–1.000)
4. Psychosocial dysfunctioning 0.724 (0.581–0.841) 0.614 (0.446–0.774)a 0.870 (0.761–0.957)
5. Childhood trauma 0.848 (0.731–0.938) 0.871 (0.765–0.957) 0.805 (0.681–0.900)
6. Previous treatment 0.757 (0.614–0.886) 0.700 (0.537–0.838) 0.833 (0.713–0.934)
Total Decision Tool score 0.771 (0.724–0.815) 0.732 (0.677–0.784) 0.808 (0.759–0.853)
a. Below the recommended level of 0.667.
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Fig. 1 Receiver-operating characteristic (ROC) curves for the Transdiagnostic Decision Tool.
(a) Total criterion validity sample (area under the ROC curve (AUC) = 0.81, 95% CI 0.76–0.86, P < 0.001) (n = 298). (b) Somatic symptom disorder (SSD) subsample (AUC = 0.84, 95% CI
0.77–0.90, P < 0.001) (n = 155). (c) Post-traumatic stress disorder (PTSD) subsample (AUC = 0.78, 95% CI 0.71–0.86, P < 0.001) (n = 143).
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provided examinations by highly trained clinicians and extensive
experience in the treatment of patients with severe and complex
mental health problems.
Second, as this study presented a first psychometric evaluation
of the Transdiagnostic Decision Tool, future studies are needed to
extend these findings. More specifically, future studies are required
to evaluate the psychometric properties of the Transdiagnostic
Decision Tool in other diagnostic groups, in patients without a
clear primary diagnosis and in other settings such as primary
care. In addition, although the validity of the Transdiagnostic
Decision Tool approximates the validity of the available diagno-
sis-specific decision tools, future studies are needed to determine
whether the Transdiagnostic Decision Tool could be used as a sub-
stitute for these available diagnosis-specific decision tools for the
diagnostic groups of personality disorders, eating disorders, uni-
polar depression and anxiety disorders. Given the time constraints
and competing clinical demands of clinicians in daily practice,34 a
trade-off should be made between validity (i.e. precision) and feasi-
bility (i.e. ease of use) of application of the Transdiagnostic Decision
Tool in all diagnoses groups.
Third, in order to enhance the feasibility of the Transdiagnostic
Decision Tool, the scoring system of the tool was constructed as a
simple, additive, unweighted sum score. Although this enhances
the ease of use in daily clinical practice, it potentially masks differ-
ences in the relative importance of individual scale items, which
may reduce the precision of the measure. Further work is required
to establish the effect of the use of a weighted score on the
psychometric properties of the Transdiagnostic Decision Tool.
Fourth, notwithstanding its favourable validity in this first
study, the Transdiagnostic Decision Tool is intended to augment
rather than replace the clinical decision-making process in the refer-
ral of patients with mental health problems to highly specialised
care. The Transdiagnostic Decision Tool has the potential to
provide indications of highly specialised care need, which, together
with an assessment of the patient’s individual circumstances, prefer-
ences and level of motivation, could motivate a referral to treatment
in a highly specialised mental healthcare setting.
Fifth, although the aim of the development of the
Transdiagnostic Decision Tool was to facilitate the provision of
matched care, the benefit of matched care in patients with a
highly specialised mental healthcare has yet to be studied. Use of
the Transdiagnostic Decision Tool in daily clinical practice could,
however, enhance the assessment of the clinical- and cost-effective-
ness of matched care in patients with a highly specialised mental
healthcare need. Finally, although the Transdiagnostic Decision
Tool was evaluated for its psychometric properties in specialised
and highly specialised mental healthcare settings, the
Transdiagnostic Decision Tool might also be of value in primary
care services. Use of the Transdiagnostic Decision Tool in
primary care services may further enhance the early identification
and timely referral of patients with mental health problems in
need of highly specialised care. Future studies are required to evalu-
ate the benefit of use of the Transdiagnostic Decision Tool in
primary care services.
Implications
Despite the limitations, the perceived ease of use, favourable
psychometric properties and the transdiagnostic applicability indi-
cate that the Transdiagnostic Decision Tool can be a promising tool
for the early identification and adequate management of patients
with mental health problems in need of highly specialised care. Its
use in daily practice could enhance the systematic and standardised
early identification of patients with a highly specialised mental
healthcare need, and thereby has the potential to enhance treatment
outcomes, reduce recidivism, reduce prolonged quality of life losses
and improve the cost-effective use of scarce healthcare resources.
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Table 4 Accuracy indices of the Transdiagnostic Decision Tool in the
total criterion validity sample (n = 298)
Decision Tool
Scale Score
Sensitivity Specificity Youden index
(J)a% 95% CI % 95% CI
≥1 97.1 93.3–99.0 25.8 18.5–34.3 0.228
≥2 87.6 81.7–92.2 53.1 44.1–62.0 0.408
≥3 72.4 65.0–78.9 75.0 66.6–82.2 0.474
≥4 50.6 42.8–58.3 90.6 84.2–95.1 0.412
≥5 24.7 18.4–31.9 96.9 92.2–99.1 0.216
6 7.1 3.7–12.0 99.2 95.7–100.0 0.068
a. Youden index = (sensitivity + specificity)− 1.
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